|
|
|
Overview
Concert Pharmaceuticals is a clinical stage biotechnology company dedicated to creating medically and commercially important new medicines through a novel approach utilizing the naturally-occurring element deuterium.
Media Contact:
Justine Koenigsberg
Senior Director, Corporate Communications and Investor Relations
781.674.5284
IR@concertpharma.com
Concert Materials and Related Stories
The following is a selection of news stories in which Concert is featured:
- January 2010, In Vivo Start Up, "Start-Ups Across Health Care - Concert Pharmaceuticals"
- January 2010, Life Science Leader, "Women In Biopharma: Analyzing The Glass Ceiling"
- November 4, 2009, Mass High Tech, "MHT All-Star Roger Tung: Life Saver"
- October 19, 2009, Chemical & Engineering News, "Rising to the Challenge; In biotech, a culture of creativity and team building helps top companies to work for weather a tough economy"
- July 2009, Drug Discovery News, "Deuterium Discovery Deal"
- June 2009, Chemical & Engineering News, "Heavy-Hydrogen Drugs Turn Heads, Again"
- June 2009, Chemistry World, "Concert Arranges Billion Dollar GSK Deal"
- May 2009, Drug Discovery & Development Magazine, "Heavy Drugs"
- March 16, 2009, Nature, "Big Interest in Heavy Drugs"
- March 9, 2009, Chemistry & Industry, "Heavyweight Drugs"
- February 19, 2009, CEO CFO, "Concert Uses the Naturally-Occurring Element Deuterium to Create First- and Best-in-Class Medicines..."
- February 2009, Watch Concert Interview on BioBusiness TV
Streaming Video ¦ High Resolution Video
Awards and Recognition
|
Mass High Tech:
Roger Tung Awarded 2009 All-Star Award |
|
|
OnDc: Named one of the OnDC's 100 Top Private Companies of 2009 |
|
5th Annual Scrip Awards: 2009 Shortlist in the category of Licensing Deal of the Year |
 |
Boston Business Journal: One of the area's largest venture-funded startups, December 2008
|
|
2008 Fierce 15 Biotechnology Company, June 2008 |
[ back to top ]
|
|
